文献速递认知障碍与痴呆

载脂蛋白E基因型对多领域生活方式干预中认知变化的影响:一项随机临床试验的亚组分析

Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2018-01-01

本研究为FINGER随机临床试验的预设亚组分析,纳入1175例有认知下降风险的老年人,其中1109例纳入分析。结果显示,在APOE ε4携带者中,干预组与对照组年度神经心理测试总分变化差值为0.037(95%CI 0.001-0.073),非携带者为0.014(95%CI -0.011-0.039),交互作用无显著差异(0.023,95%CI -0.021-0.067)。

要点

  • APOE ε4携带者干预组与对照组认知总分年变化差值为0.037(95%CI 0.001-0.073)。
  • 非携带者干预组与对照组差值为0.014(95%CI -0.011-0.039),未达统计学显著。
  • 携带者与非携带者干预效应无显著差异(交互作用0.023,95%CI -0.021-0.067)。

核心结论

  • 健康生活方式改变可能对存在APOE相关痴呆遗传易感性的老年高危人群的认知有益。
  • APOE ε4携带者与非携带者之间的干预获益是否不同需进一步研究。
  • 研究结果强调针对多种可改变危险因素同时进行早期预防策略的重要性。

研究设计与样本

  • FINGER研究为在芬兰6个中心开展的随机临床试验,筛查和随机化时间为2009年9月7日至2011年11月24日,干预持续2年。
  • 数据分析时间为2015年8月1日至2016年3月31日。
  • 研究对象为来自一般人群的老年高危个体,纳入标准为年龄60至77岁、心血管危险因素、衰老和痴呆风险评分至少6分、认知处于平均水平或略低于年龄预期。
  • 排除痴呆或显著认知障碍以及妨碍合作或安全参与干预的疾病者。
  • 1260名参与者中1175名有APOE基因型数据,最终1109名纳入改良意向性分析(至少一次基线后评估)。

主要发现

  • 共纳入1109名参与者(平均[SD]年龄69.3[4.7]岁;514名[46.3%]女性)。
  • APOE ε4携带者362名(干预组173名,对照组189名),非携带者747名(干预组380名,对照组367名)。
  • 携带者与非携带者基线特征除血清胆固醇水平外无显著差异。
  • 携带者中干预组与对照组年度神经心理测试总分变化差值为0.037(95%CI 0.001至0.073)。
  • 非携带者中干预组与对照组差值为0.014(95%CI -0.011至0.039);携带者与非携带者干预效应无显著差异(0.023,95%CI -0.021至0.067)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The role of the apolipoprotein E (APOE) ε4 allele as an effect modifier in lifestyle interventions to prevent cognitive impairment is still unclear. OBJECTIVE: To examine whether the APOE ε4 allele modifies the previously reported significant cognitive benefits of a multidomain lifestyle intervention (prespecified subgroup analysis). DESIGN, SETTING, AND PARTICIPANTS: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was a randomized clinical trial in 6 centers across Finland (screening and randomization performed from September 7, 2009, through November 24, 2011; intervention duration, 2 years). Data analysis was performed from August 1, 2015, to March 31, 2016. The study population was at-risk older individuals from the general population. Inclusion criteria were age of 60 to 77 years; Cardiovascular Risk Factors, Aging, and Dementia risk score of at least 6 points; and cognition at a mean level or slightly lower than expected for age. Individuals with dementia or substantial cognitive impairment and conditions that prevented cooperation or safe engagement in the intervention were excluded. APOE genotype data were available for 1175 of the 1260 participants. INTERVENTIONS: Participants were randomly assigned in a 1:1 ratio to a multidomain intervention group (diet, exercise, cognitive training, and vascular risk management) or a control group (general health advice). Group allocation was not actively disclosed to participants, and outcome assessors were masked to group allocation. MAIN OUTCOMES AND MEASURES: Primary outcome was change in cognition measured through a comprehensive neuropsychological test battery. Analysis was based on modified intention to treat (participants with at least 1 postbaseline assessment). RESULTS: A total of 1109 participants (mean [SD] age, 69.3 [4.7] years; 514 [46.3%] female) were included in the analysis: 362 APOE ε4 allele carriers (173 intervention and 189 control) and 747 noncarriers (380 intervention and 367 control). The APOE ε4 carriers and noncarriers were not significantly different at baseline (except for serum cholesterol level). The difference between the intervention and control groups in annual neuropsychological test battery total score change was 0.037 (95% CI, 0.001 to 0.073) among carriers and 0.014 (95% CI, -0.011 to 0.039) among noncarriers. Intervention effect was not significantly different between carriers and noncarriers (0.023; 95% CI, -0.021 to 0.067). CONCLUSIONS AND RELEVANCE: Healthy lifestyle changes may be beneficial for cognition in older at-risk individuals even in the presence of APOE-related genetic susceptibility to dementia. Whether such benefits are more pronounced in APOE ε4 carriers compared with noncarriers should be further investigated. The findings also emphasize the importance of early prevention strategies that target multiple modifiable risk factors simultaneously. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01041989.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Solomon A, Turunen H, Ngandu T, et al. Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29356827. doi:10.1001/jamaneurol.2017.4365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。